MIDLAND ENDOCRINE AND OSTEOPOROSIS LIMITEDActive

Company number 07731870Private limited companyIncorporated 2011

Key figures

£19,495+81.9%
Net assets 2024/25
-8.8%
Average annual change 2020/21–2024/25
010 k20 k30 k2020/212021/222022/232023/242024/25

Like most small UK companies, MIDLAND ENDOCRINE AND OSTEOPOROSIS LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
025 k50 k75 k2020/212021/222022/232023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand14,9947,50410,3811,4679,641
Total assets39,44411,21527,57415,84321,621
Total liabilities33,33929,25617,54116,68615,835
Net assets / total equity28,1513,44325,88310,71619,495
Average number of employees33343

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: MIDLAND ENDOCRINE AND OSTEOPOROSIS LIMITED

Company

MIDLAND ENDOCRINE AND OSTEOPOROSIS LIMITED is a private limited company registered with Companies House under company number 07731870. It was incorporated on 8 Aug 2011. Its status is active. The registered office is in Worcester (WR7). Its nature of business (SIC 2007) is other professional, scientific and technical activities n.e.c. (74909).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Aug 2025); the company files small company accounts (filleted). Net assets were £19,495, up 81.9% on the previous year. Cash at bank and in hand was £9,641. Total assets were £21,621 and total liabilities £15,835. The company had an average of 3 employees. Figures are available for 5 financial years (2020/21–2024/25).

Control and charges

2 persons with significant control are registered.

Filing deadlines

The next accounts are due by 31 May 2027. The next confirmation statement is due by 19 Sep 2027.